← Back to Home

Delivering Alpha Particles to Melanoma: Two Partial Responses in an Early VMT01 Trial

Among patients with advanced disease who had received multiple prior lines of treatment, two of eight patients in one VMT01 dose cohort had tumor shrinkage, and four had stable disease. The radiopharmaceutical has shown a preliminary efficacy signal, but the small, uncontrolled trial cannot yet answer whether it can extend survival.

By SURL BioNews

For patients with advanced melanoma whose disease continues to progress after immunotherapy, choosing the next treatment is often more difficult. An investigational drug designed to deliver radiation near tumor cells has now shown a preliminary signal of efficacy in humans: two patients in an eight-patient dose cohort in the Phase I/IIa trial of VMT01 achieved confirmed partial responses. However, these results still come from the dose-finding stage, and demonstrating clinical benefit remains some way off.

Perspective Therapeutics presented the data on November 6 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting and submitted the announcement and poster to the U.S. Securities and Exchange Commission. As of September 18, 2026, the analysis included 20 patients who received VMT01 monotherapy; they had received a median of four prior systemic therapies, and 18 had previously received immunotherapy.

VMT01, whose drug name is lapemelanotide zapixetar, targets the melanoma-associated melanocortin 1 receptor (MC1R) to deliver lead-212 to tumors, where alpha particles produced by its decay cause cellular damage. The trial first uses targeted imaging to confirm patient eligibility, applying the same targeting approach to tumor identification and subsequent treatment; the results therefore cannot be directly generalized to all patients with melanoma.

The efficacy signal was concentrated in the cohort receiving 3.0 millicuries (mCi) per dose. Based on investigator assessments using RECIST v1.1 criteria, two of eight patients had partial responses and four had stable disease, yielding a disease control rate of 75%. This proportion includes patients whose disease did not worsen and should not be interpreted as meaning that three-quarters of patients had tumor shrinkage. One additional patient had not yet reached the time for the first tumor assessment at the data cutoff; the company said that one responder continued to have a partial response approximately 40 weeks after the first treatment and remained in the study.

Neither of the other two dose cohorts had any objective responses. This makes dose selection an important question for the next stage, but it does not establish 3.0 mCi as the optimal dose: each cohort was small, and patient characteristics and follow-up duration may also have affected the results. The poster discussed mechanisms through which treatment might modulate the tumor immune environment, but their clinical role remains to be confirmed.

Regarding safety, no dose-limiting toxicities were reported among the 20 patients, and no patients discontinued treatment because of adverse events. However, this does not mean there were no serious health problems during treatment: grade 3 or higher adverse events and serious adverse events each occurred in five patients, and investigators judged all of these events to be unrelated to treatment. These causality assessments and observations from a small sample are not yet sufficient to rule out less common or later-emerging risks.

The data released this time concern monotherapy. Although the trial also includes a cohort receiving treatment in combination with the immune checkpoint inhibitor nivolumab, the poster did not provide clinical results for that cohort. At this stage, the most meaningful finding is that a small number of patients who had received multiple prior lines of treatment experienced tumor shrinkage or sustained disease stability. Determining whether this can translate into longer survival, better quality of life, and reproducible treatment effects will still require more patients, longer follow-up, and comparative studies.

References

  1. Perspective Therapeutics via SEC
  2. Perspective Therapeutics — SITC poster filed with SEC